What Is It, and Why Does It Matter?
Tecelra (afamitresgene autoleucel) is a prescription-based personalized T-cell immune therapy for treating synovial sarcoma, a rare type of cancer affecting soft tissues. The FDA granted full approval and broadened its use to include patients as young as 12 with advanced synovial sarcoma whose cancer cannot be removed surgically (unresectable) or has spread (metastatic) and who have already received chemotherapy. The approval applies to patients with specific immune system gene markers, known as HLA-A*02 variants, and whose tumors express the MAGE-A4 protein, as confirmed by FDA-approved tests.
Synovial sarcoma develops in soft tissues, most often near joints, tendons, or muscles, accounting for about 5%-10% of soft tissue sarcomas. In the U.S., about 13,400 people are diagnosed with soft tissue sarcoma each year, and about one-third of those with synovial sarcoma are under 30. Once the cancer has spread, the survival drops to about 20% at five years, with relapses commonly seen in advanced disease.
Tecelra helps your immune system identify and fight cancer cells and is made by using your own T cells, which are a type of white blood cell. Your health care provider will collect your blood and send it to a lab, where your T cells will be genetically modified to better recognize and attack cancer cells carrying specific markers (HLA-A*02 and MAGE-A4) on their surface. Once returned to your body, these modified T cells kill the cancer cells, helping to stop the cancer from growing or spreading.
In 2024, Tecelra was the first engineered T-cell treatment for a solid tumor to get the FDA's accelerated approval in the U.S. The current approval offers a new personalized treatment option for younger patients with this rare cancer.
Why Was It Approved?
The FDA's approval was based on results of a clinical study involving 137 patients with advanced synovial sarcoma who had already received chemotherapy, carried the HLA-A*02 marker, with their tumors showing the MAGE-A4 protein. Results showed that 43.8% of patients had tumor shrinkage, and 3.6% showed no signs of cancer on scans. Responses lasted a median of 5.3 months. Among those who responded to the treatment, almost 32% of patients remained responsive for 24 months or longer.
Common side effects included nausea, tiredness, muscle or joint pain, infections, fever, constipation, vomiting, headaches, diarrhea, coughing, a fast heartbeat, swelling, shortness of breath, and rashes. The most common serious side effects included cytokine release syndrome (CRS), which is a severe or life-threatening immune reaction, and infections. Many people also had low blood counts and changes in certain liver function tests.
What Do I Need to Know?
Your health care team will do certain FDA-approved tests to confirm that you or your child is eligible to receive Tecelra. You or your child will be given Tecelra once as an intravenous (IV) infusion. Before starting the treatment, your or your child's T cells will be collected by a process called leukapheresis and will be sent to a manufacturing site to create personalized T cells. However, before collecting your T cells, your health care provider may also evaluate you or your child for hepatitis B and C, HIV, the Epstein-Barr virus, and cytomegalovirus according to clinical guidelines. Your health care team will give you or your child medications before the infusion to help prepare the body.
After the infusion, your health care provider will check on you or your child daily for at least seven days. You or your child should also stay close to a facility for a minimum of two weeks to ensure that any side effects, such as CRS or nervous system problems, can be treated quickly if they happen. Do not drive or use heavy or dangerous machines for at least two weeks after receiving Tecelra, as side effects such as confusion or dizziness may show up later.
Let your health care provider know about your or your child's medical history, including heart, liver, or kidney problems; low blood pressure; lung or breathing problems; seizure, stroke, confusion, or memory loss; past infections; low blood counts; and all the medications or supplements that you or your child takes. Do not receive Tecelra if you or your child has an active infection or an inflammatory disorder.
The treatment can lower blood cell counts for weeks, increasing the risk of bleeding, bruising, fatigue, shortness of breath, and infections, including the reactivation of previous ones. Hence, regular blood monitoring is recommended. After treatment, some commercial HIV blood tests may appear positive, even if you do not have HIV.
Tecelra is not recommended during pregnancy because there is limited information on its effects on an unborn baby, so its potential fetal risks are unknown. It is also unclear whether it passes into breast milk, so women who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits with their health care provider before treatment.
Tecelra has a boxed warning for CRS, which can be life-threatening. Seek urgent help if you or your child develops a high fever, chills, trouble breathing, a very fast or irregular heartbeat, low blood pressure, severe nausea, vomiting, diarrhea, a bad headache, or a new rash.
Contact your health care provider at once if you or your child gets neurologic symptoms such as confusion, drowsiness or reduced alertness, seizures, loss of consciousness, a hard time with thinking, speech issues, or muscle weakness. These may develop due to another immune reaction known as immune effector cell-associated neurotoxicity syndrome (ICANS). Serious hypersensitivity reactions, including anaphylaxis, may also occur.